All of these findings highlight the various benefits of SGLT-2 inhibitors and GLP-1 agonists in delaying type 2 diabetes mellitus onset, reducing HbA1c levels, as well as decreasing fasting blood glucose. This evidence concerns the gene GCG and type 2 diabetes mellitus.